Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Bryant, Christopher ^a   Scriven, Kirsten ^a   Massey, Andrew J ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

Chk1; Kinase inhibitor; Leukemia; Lymphoma; V158411

Indexed keywords

CASPASE 3; CASPASE 7; CHECKPOINT KINASE 1; CYCLIN B1; CYCLIN DEPENDENT KINASE; HISTONE H2AX; PHOSPHOTRANSFERASE INHIBITOR; SERINE; THREONINE; UNCLASSIFIED DRUG; V158411; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL LINE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; COLON CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA FRAGMENTATION; ENZYME DEGRADATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; LUNG CANCER CELL LINE; LYMPHOMA CELL LINE; MITOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOLID TUMOR; CELL CYCLE CHECKPOINT; CELL DIVISION; DNA REPAIR; GENETICS; LEUKEMIA; LYMPHOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; HUMANS; LEUKEMIA; LYMPHOMA; MITOSIS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84903884326     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-147     Document Type: Article

References (38)

1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
2. Dai Y, Grant S. Targeting Chk1 in the replicative stress response. Cell Cycle 2010, 9:1025.
3. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010, 108:73-112.
4. Chen P, Luo C, Deng Y, Ryan K, Register J, Margosiak S, Tempczyk-Russell A, Nguyen B, Myers P, Lundgren K, Kan CC, O'Connor PM. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell 2000, 100:681-692.
5. Cai Z, Chehab NH, Pavletich NP. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol Cell 2009, 35:818-829.
6. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000, 14:1448-1459.
7. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, Zhang H. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003, 278:21767-21773.
8. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008, 98:523-528.
9. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005, 4:131-139.
10. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when?. Trends Pharmacol Sci 2011, 32:308-316.
11. Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008, 17:1331-1340.
12. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011, 17:88-96.
13. King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, Cox K, Guo S, Marshall M. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs 2013, 32:213-226.
14. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, Taricani L, Wiswell D, Seghezzi W, Penaflor E, Bhagwat B, Wang W, Gu D, Hsieh Y, Lee S, Liu M, Parry D. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011, 10:591-602.
15. Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 2011, 117:6074-6082.
16. Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011, 21:34-41.
17. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
18. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009, 8:24.
19. Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, Demur C, Ducommun B. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res 2009, 69:8652-8661.
20. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, Jagannathan J, Winter C, Mosse YP. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 2011, 108:3336-3341.
21. Brooks K, Oakes V, Edwards B, Ranall M, Leo P, Pavey S, Pinder A, Beamish H, Mukhopadhyay P, Lambie D, Gabrielli B. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene 2013, 32:788-796.
22. Stokes S, Foloppe N, Fiumana A, Drysdale M, Bedford S, Webb P. Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity 2009, World Intellectual Property Organisation, [WO/2009/093012]. 30-7-2009. Ref Type: Patent.
23. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008, 7:2394-2404.
24. Shibata H, Miuma S, Saldivar JC, Huebner K. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. Cancer Sci 2011, 102:1882-1888.
25. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012, 31:1661-1672.
26. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, D'Artista L, Schleker T, Guerra C, Garcia E, Barbacid M, Hidalgo M, Amati B, Fernandez-Capetillo O. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011, 18:1331-1335.
27. Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le HY, Mohr PJ, Wang B, Blake JF, Lyon MA, Gunawardana I, Chicarelli M, Wallace E, Gross S. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 2011, 19:349-363.
28. Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982, 216:1233-1235.
29. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, Brown EJ. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010, 70:9693-9702.
30. Hattori H, Skoulidis F, Russell P, Venkitaraman AR. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol Cancer Ther 2011, 10:670-678.
31. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 2009, 5:e1000324.
32. Hirvonen H, Hukkanen V, Salmi TT, Makela TP, Pelliniemi TT, Knuutila S, Alitalo R. Expression of L-myc and N-myc proto-oncogenes in human leukemias and leukemia cell lines. Blood 1991, 78:3012-3020.
33. Nishikura K, Erikson J, ar-Rushdi A, Huebner K, Croce CM. The translocated c-myc oncogene of Raji Burkitt lymphoma cells is not expressed in human lymphoblastoid cells. Proc Natl Acad Sci U S A 1985, 82:2900-2904.
34. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002, 9:1031-1044.
35. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003, 17:120-124.
36. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, Small D, Rassool F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 2008, 111:3173-3182.
37. Fan J, Li L, Small D, Rassool F. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood 2010, 116:5298-5305.
38. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. GammaH2AX and cancer. Nat Rev Cancer 2008, 8:957-967.